Skip to main content
HeXun Biosciences Co., Ltd. (TPEX:6986)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.10
-0.90 (-1.73%)
Mar 10, 2026, 1:58 PM CST

HeXun Biosciences Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
290.83286.42130.5749.47-
Revenue Growth (YoY)
14.01%119.36%163.94%--
Cost of Revenue
28.1525.7516.844.86-
Gross Profit
262.67260.67113.7344.61-
Selling, General & Admin
50.6239.5733.1414.235.95
Research & Development
84.7665.3753.2239.3644.71
Operating Expenses
135.38104.9486.3653.5950.66
Operating Income
127.29155.7327.37-8.98-50.66
Interest Expense
-1.11-1.18-1.85-1.64-1.57
Interest & Investment Income
6.14.412.790.460.03
Currency Exchange Gain (Loss)
-2.95-0.790.530.02-
Other Non Operating Income (Expenses)
3.613.34.74.939.01
EBT Excluding Unusual Items
132.95161.4833.54-5.21-43.19
Gain (Loss) on Sale of Assets
-1.62-0.01-0.050.020.2
Pretax Income
131.35161.4733.49-5.19-42.99
Income Tax Expense
19.0514.25---
Net Income
112.31147.2233.49-5.19-42.99
Net Income to Common
112.31147.2233.49-5.19-42.99
Net Income Growth
-15.76%339.62%---
Shares Outstanding (Basic)
4646453831
Shares Outstanding (Diluted)
4646453831
Shares Change (YoY)
0.06%1.61%20.81%22.92%-
EPS (Basic)
2.443.200.74-0.14-1.41
EPS (Diluted)
2.443.200.74-0.14-1.41
EPS Growth
-15.76%332.90%---
Free Cash Flow
156.2283.6322.4210-35.5
Free Cash Flow Per Share
3.391.820.490.27-1.16
Gross Margin
90.32%91.01%87.10%90.18%-
Operating Margin
43.77%54.37%20.96%-18.15%-
Profit Margin
38.62%51.40%25.65%-10.49%-
Free Cash Flow Margin
53.71%29.20%17.17%20.22%-
EBITDA
150.53175.8843.122.58-41.87
EBITDA Margin
51.76%61.41%33.03%5.21%-
D&A For EBITDA
23.2420.1515.7511.568.8
EBIT
127.29155.7327.37-8.98-50.66
EBIT Margin
43.77%54.37%20.96%-18.15%-
Effective Tax Rate
14.50%8.82%---
Source: S&P Capital IQ. Standard template. Financial Sources.